Quick Takeaways: Why It Matters? Vivesto’s Paccal Vet program could expand treatment options in veterinary oncology, an area with significant unmet needs in canine and feline cancer care. Positive preliminary findings across two species support further clinical development, ...
October 15, 2026
October 15, 2026
October 2, 2026
August 21, 2026
Load More
Quick Takeaways: Why It Matters? OST-HER2’s potential conditional licensure could give OSAH a first-mover advantage in HER2-targeted canine osteosarcoma, an area with limited treatment options. A 2027 launch could establish a differentiated oncology franchise, while validating gene-edited, Listeria-based immunotherapy as a new platform in companion animal cancer. Source: OS Animal Health...
October 7, 2026
